EVALUATING SERUM C-REACTIVE PROTEIN AND FIBRINOGEN AS PREDICTIVE BIOMARKERS FOR ULCERATIVE COLITIS EXACERBATIONS: A COMPARATIVE STUDY
DOI:
https://doi.org/10.48047/HM.V11.I2.2025.8-15Keywords:
Ulcerative colitis, C-reactive protein, FibrinogenAbstract
Ulcerative colitis (UC), a chronic inflammatory bowel disease, exhibits recurrent episodes of mucosal inflammation marked by alternating phases of remission and exacerbation. Accurate prediction of disease flares remains a clinical challenge, emphasizing the need for reliable biomarkers. This experimental study evaluates the predictive value of C-Reactive Protein (CRP) and fibrinogen levels in anticipating flare-ups in patients with confirmed UC diagnoses. A total of 120 participants were recruited and stratified into active flare-up and remission groups based on clinical, endoscopic, and histological parameters. Serum CRP and fibrinogen concentrations were quantitatively analyzed and correlated with Mayo scores and endoscopic findings. Results demonstrated significantly elevated levels of CRP (p < 0.001) and fibrinogen (p = 0.002) in the flare-up group compared to the remission cohort. Receiver Operating Characteristic (ROC) analysis identified CRP and fibrinogen as statistically significant predictors of disease exacerbation with sensitivity and specificity surpassing conventional inflammatory indices. These findings underscore the clinical utility of CRP and fibrinogen in early detection of UC flare-ups, providing a non-invasive adjunct to endoscopy. This study presents novel comparative data with strong statistical significance, potentially bridging a current gap in timely disease activity monitoring. Incorporation of these biomarkers may facilitate proactive disease management and individualized therapeutic strategies in UC care.
Downloads
References
Zhang X, Liu B, Zhang Y. Elevated C-reactive protein is associated with disease activity in ulcerative colitis patients: a cross-sectional study. Front Med. 2023;10:1171821. DOI: https://doi.org/10.3389/fmed.2023.1171821
Saleh FA, Al-Harthi SE, Kassem A. Evaluation of fibrinogen and CRP as biomarkers in inflammatory bowel disease patients. Diagnostics. 2022;12(8):1872. DOI: https://doi.org/10.3390/diagnostics12081872
Qiu Y, Mao R, Chen BL. Systematic review of non-invasive biomarkers in ulcerative colitis. Int J Colorectal Dis. 2023;38:87–99. DOI: https://doi.org/10.1007/s00384-022-04241-4
Tang J, Lin Z, Chen X. Diagnostic value of fibrinogen in ulcerative colitis activity: a prospective cohort study. Clin Transl Gastroenterol. 2022;13(4):e00481. DOI: https://doi.org/10.14309/ctg.0000000000000481
Kamal A, Zahid S, Muneeb A. Biomarkers in inflammatory bowel disease: From clinical utility to future directions. Biomed Pharmacother. 2023;162:114663. DOI: https://doi.org/10.1016/j.biopha.2023.114663
Xu X, Chen Y, Zhang X. Diagnostic performance of serum biomarkers in IBD: a comparative analysis. Clin Res Hepatol Gastroenterol. 2022;46(2):101836. DOI: https://doi.org/10.1016/j.clinre.2021.101836
Huang R, Zhou Z, Gao Y. Inflammatory markers in ulcerative colitis: prospective assessment of CRP and fibrinogen. World J Gastroenterol. 2023;29(5):711–723. DOI: https://doi.org/10.3748/wjg.v29.i5.711
Li Y, Wang Z, Guo J. Predictive value of acute phase proteins in relapse of ulcerative colitis. BMC Gastroenterol. 2022;22:49. DOI: https://doi.org/10.1186/s12876-022-02091-2
El-Matary W, Huynh HQ, Benchimol EI. Biomarkers for monitoring inflammatory bowel disease: practical relevance. Can J Gastroenterol Hepatol. 2022;2022:2486547. DOI: https://doi.org/10.1155/2022/2486547
Chen L, Li Z, Jiang Y. Role of CRP and fibrinogen as inflammatory biomarkers in ulcerative colitis: a cohort analysis. J Inflamm Res. 2023;16:489–498. DOI: https://doi.org/10.2147/JIR.S397562
Ghosh A, Basu S, Dutta S. Inflammation-driven coagulopathy in ulcerative colitis: correlation with disease activity. Clin Appl Thromb Hemost. 2022;28:10760296221107902. DOI: https://doi.org/10.1177/10760296221107902
Nawaz M, Farooq A, Raza M. Association of CRP levels with endoscopic severity in UC patients. Cureus. 2023;15(3):e35523. DOI: https://doi.org/10.7759/cureus.35523
Liu J, Xu Y, Shen J. Comparative diagnostic accuracy of biomarkers in IBD: meta-analysis update. J Clin Gastroenterol. 2024;58(1):44–52. DOI: https://doi.org/10.1097/MCG.0000000000001780
Wang W, Song H, Liu H. Serum fibrinogen as a predictor of flare in ulcerative colitis: a prospective validation. Sci Rep. 2022;12(1):2043. DOI: https://doi.org/10.1038/s41598-022-06097-z
Ahmed M, Khan MA, Jamal A. Clinical utility of CRP in differentiating UC flares from infections. J Transl Int Med. 2023;11(1):31–36. DOI: https://doi.org/10.2478/jtim-2023-0006
Yasuda H, Yamada M, Aoki H. Novel role of fibrinogen in gut barrier dysfunction during colitis. Cell Mol Gastroenterol Hepatol. 2023;15(2):367–379. DOI: https://doi.org/10.1016/j.jcmgh.2022.10.009
Salem H, Elazab S, El-Mekkawy M. Validation of composite biomarkers in UC activity: a tertiary center experience. Arab J Gastroenterol. 2022;23(4):178–185. DOI: https://doi.org/10.1016/j.ajg.2022.09.005
Zhang L, Liu L, Chen Y. Predictive capacity of non-invasive serum markers in ulcerative colitis relapse. Dig Dis Sci. 2023;68:442–449. DOI: https://doi.org/10.1007/s10620-022-07590-1
Omata F, Arai K, Takahashi S. Comparative analysis of CRP, ESR, and fibrinogen in UC: ROC-based evaluation. Clin Chim Acta. 2022;532:164–170. DOI: https://doi.org/10.1016/j.cca.2022.05.012
Kablak-Ziembicka A, Przewlocki T. Clinical significance of carotid intima-media complex and carotid plaque assessment by ultrasound for the prediction of adverse cardiovascular events in primary and secondary care patients. J Clin Med. 2021;10(20):4628. DOI: https://doi.org/10.3390/jcm10204628.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Uswa Zaib, Amna Mansoor, Muhammad Abdullah, Haiqa Tahir, Muhammad Faizan Ali, Fiza Shahbaz, Zainab Noor, Aisha Haq, Farah Naz Tahir (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
